Dismissal Of Investor Suit Over Drug Maker’s Diabetes Drug Statements Affirmed

Mealey's (September 14, 2021, 2:39 PM EDT) -- NEW ORLEANS — A Fifth Circuit U.S. Court of Appeals panel on Sept. 10 affirmed a lower court’s holding that dismissed shareholder claims against a biopharmaceutical company and certain of its...
To view the full article, register now.